About

Dr. Sharon Benzeno has served as Adaptive Biotechnologies' Chief Commercial Officer, Immune Medicine since April 2022 and leads the Drug Discovery group. She previously served as Chief Business Development Officer (2020-2022), Senior Vice President, Drug Discovery (2018-2020) and in business development roles of ascending responsibility after joining Adaptive in September 2014. Before Adaptive she was a Senior Director at Elsevier Inc., a Senior Manager in the oncology business unit at Capgemini SE, and held oncology alliance and scientific management roles at AstraZeneca plc. Dr. Benzeno holds a PhD in Biomedical Sciences from New York University School of Medicine, an MBA in Finance and Leadership from NYU's Stern School of Business and a BA in Biochemistry from NYU, and completed a postdoctoral fellowship in cancer biology at the University of Pennsylvania Abramson Cancer Center.

Roles

Adaptive Biotechnologies Corp.
Chief Commercial Officer, Immune Medicine · Current role
April 2022–present
Adaptive Biotechnologies
Chief Commercial Officer, Immune Medicine
April 2022 - present
Adaptive Biotechnologies
Chief Business Development Officer
April 2020 - April 2022
Adaptive Biotechnologies
Senior Vice President, Drug Discovery
February 2018 - April 2020
Adaptive Biotechnologies
Business development roles
September 2014 - February 2018
Elsevier Inc.
Senior Director
December 2013 - September 2014
Capgemini SE
Senior Manager, oncology business unit
May 2011 - December 2013
AstraZeneca plc
Oncology Alliance Manager and Senior Scientific Manager
September 2005 - May 2011

Also at Adaptive Biotechnologies Corp.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.